Protocol Ledger

NCT06389136 · Phase III · ACTIVE NOT RECRUITING

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Interventional Phase III clinical trial protocol NCT06389136 sponsored by AbbVie in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-14 Enrollment: 184 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06389136
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)184 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06389136
Protocol FieldVerified Registry Value
NCT IdentifierNCT06389136
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment184 participants (ACTUAL)
Registered Start Date2024-06-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI